The global market for Targeted Alpha Therapies (TAT) in cancer treatment was valued at $199.6 million in 2024, projected to reach $1.1 billion by 2030 with a CAGR of 44%. Factors driving growth include rising cancer cases, demand for precision medicines, unmet treatment needs, and strategic initiatives. Ongoing research explores new targets and combination therapies.

The report on TAT market examines key trends, revenue data, and segmentation by cancer type. Insights into competitive landscape, pipeline analysis, and company profiles are provided. Factors driving market growth include rising cancer prevalence, demand for precision medicine, unmet treatment needs, and strategic initiatives. Ongoing research expands TAT applications to new cancer types and combination therapies.

Only one approved product existed in the TAT market until recently, with Bayer taking the first mover advantage. Emerging startups are entering the market through strategic initiatives such as licensing, collaboration, and acquisitions. The pipeline analysis suggests approval and launch of two TAT products by 2030, targeting neuroendocrine tumors and prostate cancer.

The global TAT market is expected to grow at a CAGR of 44% from 2025 to 2030, reaching $1.1 billion. Factors driving growth include rising cancer cases, demand for precision medicines, unmet treatment needs, and strategic initiatives. Ongoing research offers opportunities for new targets and combination therapies, with the prostate cancer segment expected to dominate.

Market leaders in the TAT industry include ACTINIUM PHARMACEUTICALS INC., BAYER AG, NOVARTIS AG, and others. The North American region holds the largest market share. The market is segmented by cancer type, with prostate cancer expected to dominate through 2030. Opportunities for growth include ongoing research for new targets and combination therapies.

Read more at GlobeNewswire: Targeted Alpha Therapies Market to Grow at 44% CAGR